Exhibit 10.1

EXECUTION COPY

SEPARATION AND RELEASE AGREEMENT

THIS SEPARATION AND RELEASE AGREEMENT (this “Agreement”), dated as of March 22, 2024, is by and between The Chemours Company (the “Company”), and Mark E. Newman (“Executive”). The Company and Executive are hereinafter referred to as the “Parties”.

WHEREAS, Executive has been employed by the Company as its President and Chief Executive Officer of the Company and a member of the Board of Directors of the Company (the “Board”);

WHEREAS, the Company and Executive have mutually agreed that Executive will voluntarily resign from his roles as President and Chief Executive Officer of the Company and as a member of the Board;

WHEREAS, the Company and Executive desire to set forth their respective rights and obligations in respect of Executive’s separation from the Company.

NOW, THEREFORE, in consideration of the covenants and conditions set forth herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:

1. Resignations on Termination Date. Executive and the Company agree that, effective March 22, 2024 (the “Termination Date”), Executive shall resign from his positions as President and Chief Executive Officer of the Company and from any other positions held by Executive with the Company and its subsidiaries and affiliates, including as a member of the Board, and Executive’s employment with the Company and all of its affiliates will permanently terminate on the Termination Date. Executive hereby agrees that no further action is required by Executive or any of the preceding to make the terminations provided for in this Section 1 effective, but Executive nonetheless agrees to execute (or to allow the Company’s officers to execute on Executive’s behalf) any additional documentation as may be requested by the Company in connection therewith and solely for the purpose of effectuating such resignations, and to not reassume any such service or position.

2. Equity Award Treatment. Subject to the terms of this Agreement and the applicable plan and award agreement, Executive’s execution of the release of claims in the form attached as Exhibit A to this Agreement (the “Release”) within twenty-one (21) calendar days following the Termination Date, and the non-revocation of the Release during the seven (7)-day period following execution of the Release, Executive shall be entitled to the treatment of his outstanding Company stock options that are vested as of immediately prior to the date hereof as set forth in clauses (a) and (b) below (collectively, the “Stock Option Benefits”), and all other outstanding equity awards, including the unvested stock options and restricted stock units granted to Executive and the performance stock units granted to Executive in 2021, 2022 and 2023 shall be forfeited in full immediately on the Termination Date for no consideration. Executive may exercise any vested Company stock options exercisable as a result of the Stock Option Benefits using the exercise methodologies available under the applicable award agreement and the Company’s standard practices as in effect from time to time.

a. For purposes of Executive’s vested Company stock options granted on or after April 26, 2017, Executive will be treated as if, upon the Termination Date, Executive had attained age 60 with at least 10 years of service, and such awards will remain exercisable through the date that is three (3) years after the Termination Date (or, if earlier, the expiration date set forth in the applicable award agreement), subject to Executive’s refraining from engaging in the restricted conduct activities described under the section entitled “Restricted Conduct” in the applicable award agreement and complying with this Agreement.

b. For purposes of Executive’s vested Company stock options granted prior to April 26, 2017, Executive will be treated as if, upon the Termination Date, Executive had attained age 55 with at least 10 years of service, and such awards will remain exercisable through the expiration date set forth in the applicable award agreement, subject to Executive’s refraining from engaging in the restricted conduct activities described under the section entitled “Restricted Conduct” in the applicable award agreement and complying with this Agreement.

3. Acknowledgements. Executive further agrees and acknowledges that (a) the Company has paid Executive all salary and wages due to Executive with respect to Executive’s services to the Company through the Termination Date (including any accrued and unused paid time off in accordance with Company policy) and will pay or provide Executive’s vested benefits under the Company’s Retirement Savings Restoration Plan (401(k)), Management Deferred Compensation Plan and other Company employee benefit plans in which Executive participated as of the Termination Date (including, without limitation COBRA continuation coverage) in accordance with the terms thereof and any payment elections thereunder, and there are no other accrued but unpaid amounts to which Executive is entitled, (b) Executive is not otherwise eligible for or entitled to the Stock Option Benefits provided under Section 2, and such benefits are adequate and sufficient consideration in exchange for the Release, (c) Executive will not be entitled to a 2023 or 2024 annual cash incentive award, a 2024 equity or equity-based award or any compensation or benefits in connection with Executive’s termination, including severance, separation or termination pay or benefits under the Company’s Senior Executive Severance Plan or any other plan, program, policy or practice, (d) except as specifically provided above in Section 2 with respect to the vested stock options, all of Executive’s outstanding equity and equity-based awards will be irrevocably forfeited and cancelled for no consideration as of the Termination Date, and (e) Executive and any amounts or benefits previously paid or provided to Executive, including the vested stock options addressed in Section 2, remain subject to the terms of the applicable plans and award agreements, all of the Company’s policies and procedures, including the Incentive Compensation Clawback Policy and the Company’s Incentive-Based Compensation Clawback Policy for Executive Officers.

4. Full Settlement; Cooperation; Indemnification; Return of Property.

a. Full Settlement. Except as expressly provided herein, Executive agrees that the Stock Option Benefits contemplated by Section 2 of this Agreement shall be in full satisfaction of any rights and benefits due to Executive upon a termination of Executive’s employment with the Company.

-2-

b. Cooperation. Executive agrees to continue to cooperate with the Company and its respective directors, officers, employees, attorneys and experts in connection with the Board’s continued review with respect to the Company’s accounting, including, to the extent applicable, Executive’s conduct with respect to the same. Such cooperation and assistance shall include, but not be limited to, promptly providing information and documents and providing general cooperation to assist the Company. The Company will, to the extent feasible, use reasonable business efforts to provide Executive with reasonable notice in the event Executive’s assistance is required and to schedule any meetings and the timing of any document production in such manner as would not materially interfere with Executive’s other business and personal commitments. The Company will pay or reimburse Executive for all reasonable out-of-pocket travel, duplicating or telephonic expenses incurred by Executive in complying with the cooperation obligations hereunder, and such entitlement will in no way affect other rights that Executive has to be indemnified or advanced expenses under the “Indemnification Agreement” (as defined below) or the Company’s organizational documents.

c. Indemnification; D&O Coverage. The Company acknowledges that the Indemnification Agreement between Executive and the Company, dated as of February 23, 2016 (the “Indemnification Agreement”) and any similar rights under the Company’s organizational documents shall survive the Termination Date in accordance with the terms thereof. In addition, the Company shall continue to cover Executive under directors’ and officers’ liability insurance following the Termination Date in the same amount and to the same extent as the Company covers its other active officers and directors.

d. Return of Property. By signing this Agreement, Executive certifies that (i) he has returned to the Company all documents, materials, equipment, and devices in his possession, custody or control that are the property of the Company; (ii) after returning such property to the Company, Executive has not retained any copies of any confidential information and/or any other materials, documents and/or property belonging to the Company; and (iii) Executive has delivered to the Company all confidential information on his home and/or personal computer drives and from any other personal electronic, digital or magnetic storage devices. For the avoidance of doubt, the Company will cooperate with Executive to provide him with a copy of his rolodex and similar contact information, and Executive will be permitted to retain copies of relevant benefit plan documents for benefit plans in which Executive participated as of the Termination Date.

e. Remedies. Material violations of this Agreement shall result in the immediate forfeiture of any then-outstanding equity awards and entitle the Company to repayment by Executive of any benefits previously received in respect of the Stock Option Benefits. Executive agrees that the foregoing will not invalidate this Agreement or the Release, and acknowledges that Executive will continue to be bound by the terms of this Agreement and the Release. Executive acknowledges that the Company may be irreparably injured by his violation of this Agreement and that in the event of any breach or threatened breach, the Company shall, in addition to any other remedies available to it, be entitled to seek: (i) a temporary restraining order and/or preliminary and/or permanent injunction, or other equivalent relief, restraining Executive from any actual or threatened breach of this Agreement; (ii) damages, to partially offset the irreparable damage such a violation would cause; and (iii) attorneys’ fees and other costs incurred by the Company in obtaining such relief. Nothing in this Agreement shall limit or prevent the Company from also pursuing any other or additional remedies it may have for breach of this Agreement and/or any other agreement Executive may have signed.

-3-

5. Tax Withholding. All payments and benefits provided to Executive under this Agreement will be less applicable withholdings for federal, state and local taxes.

6. Entire Agreement. This Agreement and the Release constitute the entire agreement between the Parties with respect to the subject matter hereof, and supersede any and all prior agreements or understandings between the Parties arising out of or relating to Executive’s employment and the cessation thereof.

7. Governing Law; Jurisdiction. This Agreement shall be governed by the laws of the State of Delaware, without giving effect to the conflicts of law principles thereof. Any disputes regarding this Agreement shall be brought only in the Delaware Chancery Court in Wilmington, Delaware or the U.S. District Court for the District of Delaware.

8. Severability of Provisions. Each of the sections contained in this Agreement shall be enforceable independently of every other section in this Agreement, and the invalidity or nonenforceability of any section shall not invalidate or render unenforceable any other section contained in this Agreement.

9. Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the successors and assigns of the Company, including as a result of a merger or sale of all or substantially all of the Company’s assets or similar corporate transaction. This Agreement shall not be assignable by Executive.

10. Waivers. No failure on the part of either Party to exercise, and no delay in exercising, any right or remedy under this Agreement shall operate as a waiver thereof; nor shall any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy granted hereby or by any related document or by law.

11. Modification. No supplement, modification, or amendment of this Agreement shall be binding unless executed in writing by both Executive and the Company.

12. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall be one and the same instrument.

[Remainder of page intentionally left blank.]

-4-

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the day and year first above written.

[Signature Page to Separation and Release Agreement]

EXHIBIT A

THIS RELEASE (this “Release”) is entered into between Mark E. Newman (“Executive”) and The Chemours Company (the “Company”), for the benefit of the Company. Reference is made to the Separation and Release Agreement (the “Separation Agreement”), dated March 22, 2024, by and between the Company and Executive. Capitalized terms used and not defined herein shall have the meanings provided in the Separation Agreement. The entering into and non-revocation of this Release is a condition to Executive’s right to receive the treatment of Executive’s vested stock options described in Section 2 of the Separation Agreement (the “Stock Option Benefits”).

Accordingly, Executive and the Company agree as follows:

1. In consideration for the Stock Option Benefits, to which Executive is not otherwise entitled, and the sufficiency of which Executive acknowledges, Executive represents and agrees, as follows:

(a) Executive, for himself, his heirs, administrators, attorneys, representatives, executors, successors and assigns (collectively “Releasers”), hereby irrevocably and unconditionally releases, acquits and forever discharges and agrees not to sue the Company or any of its parents, subsidiaries, divisions, affiliates and related entities and their current and former directors, officers, and, in their official capacities as such, shareholders, trustees, employees, consultants, independent contractors, representatives, agents, servants, successors and assigns and all persons acting by, through or under or in concert with any of them (collectively “Releasees”), from all claims, rights, causes of action, contracts, liabilities, agreements, promises, torts, rights, up to and including the date of this Release, arising from or relating to Executive’s employment with (including service as a director), or termination of employment from (including termination of service as a director), the Company and its subsidiaries and affiliates, and from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, controversies, damages, actions, causes of actions, suits, rights, demands, costs, losses, debts and expenses in connection with Executive’s service as a director of the Company and Executive’s employment and termination of employment with the Company and its subsidiaries, known or unknown, suspected or unsuspected and any claims of wrongful discharge, breach of contract, implied contract, promissory estoppel, defamation, slander, libel, tortious conduct, employment discrimination or claims under any federal, state or local employment statute, law, order or ordinance, including any rights or claims arising under Title VII of the Civil Rights Act of 1964, as amended, the Age Discrimination in Employment Act of 1967, as amended, 29 U.S.C. § 621 et seq. (“ADEA”), the Americans with Disabilities Act of 1990, as amended, the Family and Medical Leave Act of 1993, as amended, the Employee Retirement Income Security Act of 1974, as amended, the Equal Pay Act of 1963, the Fair Labor Standards Act, Section 1981 of U.S.C. Title 42, the Fair Credit Reporting Act, the National Labor Relations Act, the Uniformed Services Employment and Reemployment Rights Act, the Genetic Information Nondiscrimination Act, the Immigration Reform and Control Act, the Vietnam Era Veterans’ Readjustment Assistance Act of 1974, as amended, and the Worker Adjustment and Retraining Notification Act of 1988, as amended. Nothing contained herein shall restrict the Parties’ rights to enforce the terms of this Release.

A-1

(b) To the maximum extent permitted by law, Executive agrees that he has not filed, nor will he ever file, a lawsuit asserting any claims which are released by this Release, or to accept any benefit from any lawsuit which might be filed by another person or government entity based in whole or in part on any event, act, or omission which is the subject of this Release.

(c) This Release does not waive rights or claims with respect to (i) Executive’s rights to the Stock Option Benefits, (ii) Executive’s rights as a stockholder of the Company, (iii) claims which may not be released under applicable law, (iv) Executive’s rights to accrued but unpaid salary or paid time off accrued through the Termination Date and any vested benefits under the Company’s 401(k) plan, Retirement Savings Restoration Plan and Management Deferred Compensation Plan, (v) continuation coverage benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, (vi) any unreimbursed reimbursable business expenses, (vii) any rights under this Separation Agreement or the Indemnification Agreement and any similar rights under the Company’s organizational documents, and (viii) any claims that may arise after the date this Release is executed. Nothing contained in this Release shall release Executive from his obligations under the Separation Agreement or any other agreement between Executive and the Company (including the obligations under the heading entitled “Restricted Conduct” in each applicable equity award agreement) that continue or are to be performed following Executive’s termination of employment with the Company, and Executive acknowledges that the Company will have available to it all remedies under the Separation Agreement and at law and at equity, including injunctive relief, in the event that Executive breaches any of his obligations under the Separation Agreement, any other agreement between Executive and the Company or this Release. The covenants, representations and acknowledgments made by Executive in this Release shall continue to have full force and effect after the execution and effectiveness of this Release and the delivery of the Stock Option Benefits, and this Release shall inure to the benefit of each Releasee, and the successors and assigns of each of them, to the extent necessary to preserve the intended benefits of such provisions.

(d) The Parties agree that the Separation Agreement and this Release shall not affect the rights and responsibilities of the U.S. Equal Employment Opportunity Commission (hereinafter “EEOC”) to enforce ADEA and other laws. In addition, the Parties agree that the Separation Agreement and this Release shall not be interpreted to prohibit or restrict Executive from filing a charge or initiating communications directly with or responding to any inquiry from or participating in (including providing testimony for) an investigation or proceeding conducted by the EEOC, the Securities and Exchange Commission (“SEC”) or other government agency or making other disclosures that are protected under whistleblower provisions of federal law or regulation or from otherwise making disclosures protected under whistleblower provisions of federal law or regulation (including Section 21F of the Securities Exchange Act of 1934 and the regulations promulgated thereunder) or limit Executive’s right to receive an award for information provided to the SEC or any other securities regulatory agency, in each case without the necessity of prior authorization from the Company or the need to notify the Company that he has done so. The Parties further agree that Executive knowingly and voluntarily waives all rights or claims (that arose prior to Executive’s execution of this Release) the Releasers may have against the Releasees, or any of them, to receive any benefit or remedial relief (including, but not limited to, reinstatement, back pay, front pay, damages, attorneys’ fees, experts’ fees) as a consequence of any investigation or proceeding conducted by the EEOC.

A-2

Executive acknowledges that the Company has specifically advised him of the right to seek the advice of an attorney concerning the terms and conditions of this Release. Executive further acknowledges that he has been furnished with a copy of this Release, and he has been afforded twenty-one (21) calendar days in which to consider the terms and conditions set forth above prior to this Release. By executing this Release, Executive affirmatively states that he has had sufficient and reasonable time to review this Release and to consult with an attorney concerning his legal rights prior to the final execution of this Release. Executive further agrees that he has carefully read this Release and fully understands its terms. Executive acknowledges that he has entered into this Release, knowingly, freely and voluntarily. Executive understands that he may revoke this Release within seven (7) calendar days after signing this Release. Revocation of this Release must be made in writing and must be received by Kristine M. Wellman at the Company, 1007 Market Street, C-51, Wilmington, DE 19801, within the time period set forth above.

2. This Release covers both claims that Executive knows about and those Executive may not know about. Executive expressly waives all rights afforded by any statute which limits the effect of a release with respect to unknown claims. Executive understands the significance of Executive’s release of unknown claims and Executive’s waiver of statutory protection against a release of unknown claims.

3. This Release will be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflicting provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the laws of any jurisdiction other than the State of Delaware to be applied. In furtherance of the foregoing, the internal law of the State of Delaware will control the interpretation and construction of this agreement, even if under such jurisdiction’s choice of law or conflict of law analysis, the substantive law of some other jurisdiction would ordinarily apply. The provisions of this Release are severable, and if any part or portion of it is found to be unenforceable, the other paragraphs shall remain fully valid and enforceable.

A-3

4. This Release shall become effective and enforceable on the eighth day following its execution by Executive, provided he does not exercise his right of revocation as described above. If Executive fails to sign and deliver this Release or revokes his signature, this Release will be without force or effect, and Executive shall not be entitled to the Stock Option Benefits.

[Signature Page to Release]

Exhibit 99.1

Chemours Announces Appointment of Denise Dignam as President

and Chief Executive Officer of the Company

Wilmington, Del., March 22, 2024 – The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials, today announced the appointment of Denise Dignam, current Interim Chief Executive Officer, to the positions of President and Chief Executive Officer and a member of the Board of Directors, effective immediately.

Ms. Dignam joined Chemours in 2015. She brings over 35 years of experience in the chemical industry where she has held senior roles in business and operations, sales and marketing, commercialization, and supply chain. She had served as Interim Chief Executive Officer since February 2024, and prior to that held the positions of President, Titanium Technologies (TT) segment, and President, Advanced Performance Materials (APM) segment—two businesses that represent over 68% of Chemours’ net sales in 2023. As President of Titanium Technologies, Ms. Dignam stood up the TT Transformation Plan, delivered significant operational savings in 2023, refocused the portfolio to deliver more customer value, and developed process improvements for better resource utilization across the manufacturing circuit. During her tenure on Advanced Performance Materials, she reshaped the portfolio to focus resources on secular growth opportunities in Clean Energy and Advanced Electronics. To further accelerate growth, she drove strategic partnerships and initiatives across the globe, and improved the overall cost structure of the business, laying the foundation for further cost optimization.

Commenting on her appointment, Ms. Dignam said, “I am excited and honored to take on the role of President and CEO. Chemours is defined by its leading chemistries, the customer applications that our chemistries enable, our manufacturing capabilities, and as importantly, our people and core values. Looking ahead I will be focused on strengthening our portfolio with high-value and emerging growth opportunities, and ensuring we are operating as efficiently, effectively, and safely as possible. I am committed to continuing to lead with transparency as we do the hard work required to keep building our businesses for today and into the future. I want to thank our Chemours employees around the world, who are the cornerstone of our success, and our customers and partners for their continued support.”

Dawn Farrell, Chair of the Board of Chemours, added, “Denise has the full support of the Board, and we are pleased to have an experienced and capable executive who is so highly regarded inside and outside Chemours for her track record leading the APM and TT business segments. Denise is a high-caliber leader who has the experience and capability to build value for shareholders while upholding our core values and serving our valued customers.”

Additional Leadership Changes

Matthew S. Abbott, Interim Chief Financial Officer (CFO), will continue in his role while we commence a comprehensive search for a permanent CFO.

“Matt is an incredible partner,” said Ms. Dignam. “His tireless efforts and leadership have been integral to Chemours’ progress to this point and will continue to be critical as we navigate the road ahead of us. Matt has made it clear that he is committed to leading the Finance organization, building a strong controls environment, and ensuring the delivery of our financial reporting and disclosures, while we conduct our search for a permanent CFO to further enhance our capital structure and achieve shareholder value.”

Diane Iuliano Picho, Vice President of Human Resources and Chief of Staff, Titanium Technologies, will step in as Interim President, Titanium Technologies while we conduct a comprehensive search for a permanent segment President. Diane brings to the role demonstrated business acumen over a 40-year career that includes experiences in R&D, operations, HR, sales, marketing, and commercial leadership. Previously, Diane was the Vice President of Commercial Operations for the Advanced Performance Materials segment where she led product management, supply chain and demand planning, and competitive intelligence. Before Chemours, Diane held business roles of increasing responsibility at E.I. du Pont de Nemours, which she joined in 1983. During that time, as Global Business Manager of Refrigerants, she led the product development, IP strategy, commercialization, and launch of the company’s Opteon^™ low global warming potential refrigerant offering. She received her Master of Business Administration from Widener University and her Bachelor of Science in Mechanical Engineering from Villanova University.

About The Chemours Company

The Chemours Company (NYSE: CC) is a global leader in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials providing its customers with solutions in a wide range of industries with market-defining products, application expertise and chemistry-based innovations. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, and oil and gas. Our flagship products are sold under prominent brands such as Ti-Pure^™, Opteon^™, Freon^™, Teflon^™, Viton^™, Nafion^™, and Krytox^™. The company has approximately 6,200 employees and 28 manufacturing sites serving approximately 2,700 customers in approximately 110 countries. Chemours is headquartered in Wilmington, Delaware and is listed on the NYSE under the symbol CC.

For more information, we invite you to visit chemours.com or follow us on X (formerly Twitter) @Chemours or on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words “believe,” “expect,” “will,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the focus on strengthening Chemours’ portfolio with high-value and emerging growth opportunities, and ensuring Chemours is operating efficiently, effectively, and safely as possible, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized, such as full year guidance relying on models based upon management assumptions regarding future events that are inherently uncertain.

These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours’ control. Matters outside our control, including general economic conditions, geopolitical conditions and global health events, have affected or may affect our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains such as through strikes, labor disruptions or other events, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2022 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

INVESTORS

Brandon Ontjes

VP, Financial Planning & Analysis, and Investor Relations

+1.302.773.3300

investor@chemours.com

Kurt Bonner

Manager, Investor Relations

+1.302.773.0026

investor@chemours.com

NEWS MEDIA

Cassie Olszewski

Corporate Media & Brand Reputation Leader

+1.302.219.7140

media@chemours.com